Thinking of joining a study?

Register your interest

Become a volunteer?

NCT06937268 | NOT YET RECRUITING | Meningioma

DOTATATE PET for Meningioma Radiation Planning
Sponsor:

British Columbia Cancer Agency

Brief Summary:

68Ga-DOTATATE-based radionuclides are a novel modality in the diagnosis and treatment of central nervous system meningioma. DOTATATE is a ligand for the SSTR (somatostatin receptor), which is expressed in meningioma but not in normal brain or bone. It is also more effective than MRI in delineating tumor, which is the current imaging standard for assessing meningioma. For radiation planning, it can help to reduce the risk of geometrical miss, identify area that require dose-escalation, and reduce dose to normal tissue. The purpose of the study is to compare the radiation therapy (RT) contouring and planning for meningioma with and without the use of 68Ga-DOTATATE-PET

Condition or disease

Meningioma

Intervention/treatment

DOTATATE-PET scan

Phase

NA

Study Type : INTERVENTIONAL
Estimated Enrollment : 36 participants
Masking : NONE
Primary Purpose : TREATMENT
Official Title : Exploratory Analysis of DOTATATE PET for Meningioma Radiation Planning
Actual Study Start Date : 2025-06
Estimated Primary Completion Date : 2026-12-31
Estimated Study Completion Date : 2027-12-31

Information not available for Arms and Intervention/treatment

Ages Eligible for Study: 18 Years
Sexes Eligible for Study: ALL
Accepts Healthy Volunteers:
Criteria
Inclusion Criteria
  • * Age ≥ 18 years old
  • * Able and willing to comply with the study procedures
  • * Intact meningioma requiring definitive radiation
  • * Post-operative meningioma requiring adjuvant radiation
  • * No prior radiation therapy or medical therapy directed at the tumour
Exclusion Criteria
  • * Breastfeeding or pregnancy
  • * Claustrophobia or inability to lie still in a supine position
  • * Unwillingness or inability to provide informed consent
DOTATATE PET for Meningioma Radiation Planning

Location Details

NCT06937268

Please Choose a site

How to Participate

Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.

Locations

Not yet recruiting

Canada, British Columbia

BC Cancer - Vancouver

Vancouver, British Columbia, Canada, V5Z 4E6